News
Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...
Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...
Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...
Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...
Eisai (OTCPK:ESALF) and Eli Lilly (NYSE:LLY) on Wednesday announced data from long-term extension studies for their ...
Long-term treatment with lecanemab shows slowed progression of early Alzheimer’s disease, according to data presented at the ...
Eisai has presented new clinical data showing that patients with early Alzheimer’s disease continue to benefit from four years of treatment with Leqembi (lecanemab). Findings were shared at the ...
Eisai's groundbreaking presentation at the Alzheimer's Association International Conference has revealed a potential game-changer for Alzheimer's treatment that could transform both patient care and ...
Eisai Makes Steady Progress In Partnership With Biogen In June 2021, Aduhelm, developed by Biogen Inc. (BIIB), received FDA's accelerated approval as the first and only Alzheimer's disease treatment.
CHICAGO, Sept 30 (Reuters) - Clear evidence this week that Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab drug lecanemab slows cognitive decline in early stage dementia has ...
Japanese drugmaker Eisai said on Tuesday it was targeting revenue of 10 billion yen ($66.5 million) from its recently approved Alzheimer's drug, Leqembi, by March 2024.
Eisai is continuing to advance care in Alzheimer’s disease via this multi-dimensional, yet targeted path to our ultimate goal: prevention and stopping progression.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results